Dengue Vaccines Regulatory Pathways: A Report on Two Meetings with Regulators of Developing Countries
2011

Dengue Vaccines Regulatory Pathways

publication Evidence: moderate

Author Information

Author(s): Richard Mahoney, Liliana Chocarro, James Southern, Donald P. Francis, John Vose, Harold Margolis

Primary Institution: Dengue Vaccine Initiative, International Vaccine Institute

Conclusion

The study highlights the regulatory challenges and considerations necessary for the development and licensing of dengue vaccines.

Supporting Evidence

  • Dengue vaccines must be tetravalent to protect against all four dengue serotypes.
  • Safety assessments need to consider the risk of antibody-dependent enhancement.
  • Regulatory agencies in endemic countries need support for reviewing vaccine applications.

Takeaway

This paper talks about the rules and steps needed to make sure dengue vaccines are safe and effective before they can be used in people.

Limitations

The paper does not provide specific data on vaccine efficacy or safety outcomes from clinical trials.

Digital Object Identifier (DOI)

10.1371/journal.pmed.1000418

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication